- Home
- NRC vs ABEO Comparison
NRC vs ABEO Comparison
Compare NRC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- ABEO
- Stock Information
- Founded
- NRC 1981
- ABEO 1974
- Country
- NRC United States
- ABEO United States
- Employees
- NRC N/A
- ABEO N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- ABEO Health Care
- Exchange
- NRC Nasdaq
- ABEO Nasdaq
- Market Cap
- NRC 354.5M
- ABEO 332.0M
- IPO Year
- NRC N/A
- ABEO 1980
- Fundamental
- Price
- NRC $14.65
- ABEO $6.83
- Analyst Decision
- NRC
- ABEO Strong Buy
- Analyst Count
- NRC 0
- ABEO 6
- Target Price
- NRC N/A
- ABEO $18.17
- AVG Volume (30 Days)
- NRC 101.8K
- ABEO 702.3K
- Earning Date
- NRC 10-24-2025
- ABEO 08-14-2025
- Dividend Yield
- NRC 3.27%
- ABEO N/A
- EPS Growth
- NRC N/A
- ABEO N/A
- EPS
- NRC 0.77
- ABEO 0.99
- Revenue
- NRC $140,314,000.00
- ABEO $400,000.00
- Revenue This Year
- NRC N/A
- ABEO N/A
- Revenue Next Year
- NRC N/A
- ABEO $339.63
- P/E Ratio
- NRC $19.08
- ABEO $6.91
- Revenue Growth
- NRC N/A
- ABEO N/A
- 52 Week Low
- NRC $9.76
- ABEO $3.93
- 52 Week High
- NRC $22.99
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- NRC 47.80
- ABEO 52.71
- Support Level
- NRC $14.45
- ABEO $6.70
- Resistance Level
- NRC $15.60
- ABEO $7.15
- Average True Range (ATR)
- NRC 0.64
- ABEO 0.31
- MACD
- NRC -0.03
- ABEO -0.02
- Stochastic Oscillator
- NRC 17.05
- ABEO 46.62
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.